Paul S. Jin

Paul S. Jin

Paul S. Jin
Washington, DC
+1 202 346 4013

Paul Jin is a partner in Goodwin's Antitrust and Competition practice. Paul’s antitrust expertise covers a broad spectrum of commercial transactions, including mergers and acquisitions, B2B collaborations, and pricing and supply arrangements. Paul regularly serves clients by assessing transaction-related antitrust risk, negotiating terms of agreements, and determining the applicability of merger clearance filing requirements in both US and foreign jurisdictions. Paul routinely advocates on behalf of clients before the FTC, DOJ, and state regulators in connection with informal inquiries, Second Requests, third-party subpoenas, and conduct investigations. He also provides antitrust counseling on issues such as diligence and pre-closing conduct procedures, internal compliance programs, hiring and non-compete agreements, vendor agreements, interlocking directorates, and competitor collaboration guidelines. He has extensive knowledge of the Hart-Scott-Rodino (HSR) regime and has filed hundreds of notification forms with the FTC and DOJ for mergers, minority investments, asset acquisitions, and corrective fillings.

Prior to joining Goodwin in 2018, Paul was a partner in the antitrust practice at Wilson Sonsini Goodrich & Rosati, and previously practiced at Fried, Frank, Harris, Shriver & Jacobson LLP.


Select representations include:

  • Nanobiotix in its licensing, co-development, and commercialization agreement with Janssen for up to $1.8 billion
  • eMagin Corporation to be acquired by Samsung Display for $218 million
  • Berkshire Grey in its definitive merger agreement to be acquired by SoftBank Group
  • Marlin Equity Partners in its acquisition of Meltwater
  • Nimbus Therapeutics in its sale of Allosteric Tyk2 Inhibitor Program to Takeda for $4 billion upfront and up to $6 billion total following antitrust litigation against Celgene and Bristol Myers Squibb to enjoin their attempted acquisition of the same program 
  • Jemincare in its exclusive worldwide license agreement with Roche and Genentech for the development and commercialization of its androgen receptor degrader
  • Thoma Bravo in its acquisition of Nearmap for AUD $1.055 billion
  • Klaviyo in its product partnership with Shopify and on Shopify’s strategic investment in Klaviyo
  • Coalition in its $250 million Series F financing
  • BridgeBio Pharma in its exclusive license agreement with Bristol Myers Squibb for up to $905 million and sale of rare pediatric disease priority review voucher for $110 million
  • Slack Technologies, Inc. in its $27.7 billion acquisition by Salesforce
  • Virtusa Corporation in its $2 billion acquisition by Baring Private Equity Asia
  • Lucid Holdings in its $1.1 billion acquisition by Cint Group AB
  • Great Hill Partners in its acquisition of a controlling equity stake in Clearwave Parent, Inc. at an enterprise value of $300 million
  • The creation of Beth Israel Lahey Health
  • Twilio in its acquisition of SendGrid
  • The independent directors of Sprint Corporation in their merger with T-Mobile USA
  • PillPack, Inc. in its acquisition by Amazon
  • Qualtrics in its acquisition by SAP SE
  • AppNexus in its acquisition by AT&T
  • Moovit in its acquisition by Intel




Northwestern University School of Law


Duke University


U.S. Senate Committee on the Judiciary Subcommittee on Antitrust, Competition Policy, and Consumer Rights



  • District of Columbia
  • Virginia

Recognition & Awards

Paul is recommended for Antitrust - Merger Control and Healthcare: Life Sciences by The Legal 500 United States (2019-2023). Paul Jin was recognized by LMG Life Sciences Americas Awards 2023 for Impact Deal of the Year Award as a member of the team which advised Sichuan Kelun-Biotech Biopharmaceutical in its $9.5 billion exclusive license and collaboration agreement with Merck to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.


Speaking engagements:

  • Speaker, “Private Equity Planning for Post COVID-19: An Antitrust Roadmap for PE Investment,” Goodwin Webinar, July 2020
  • Speaker, “Life Sciences Deals & Antitrust in the Age of COVID-19,” Goodwin Webinar, May 2020
  • Panelist, “Caveat Emptor: When are buying groups illegal?” ABA Section of Antitrust Law Spring Meeting, Washington, D.C., April 2016
  • Speaker, “The Hart-Scott-Rodino Act: Recognizing Covered Transactions,” Knowledge Group Webcast, February 2016
  • Speaker, “Mitigating Antitrust Risks in Mergers & Acquisitions Transactions: What Every Firm Needs to Know in 2015,” Knowledge Group Webcast, June 2015